Ascendiant Capital Markets Comments on ATOS Q1 Earnings

Atossa Therapeutics, Inc. (NASDAQ:ATOS) – Stock analysts at Ascendiant Capital Markets issued their Q1 2026 earnings per share estimates for Atossa Therapeutics in a report issued on Sunday, April 20th. Ascendiant Capital Markets analyst E. Woo expects that the company will earn ($0.06) per share for the quarter. Ascendiant Capital Markets has a “Buy” rating and a $7.25 price objective on the stock. The consensus estimate for Atossa Therapeutics’ current full-year earnings is ($0.22) per share. Ascendiant Capital Markets also issued estimates for Atossa Therapeutics’ Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS and Q4 2026 earnings at ($0.06) EPS.

Separately, HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Atossa Therapeutics in a report on Wednesday, March 26th.

Atossa Therapeutics Stock Up 11.2 %

NASDAQ ATOS opened at $0.74 on Wednesday. The company’s 50 day moving average is $0.70 and its 200-day moving average is $0.99. The firm has a market cap of $95.33 million, a P/E ratio of -3.35 and a beta of 1.46. Atossa Therapeutics has a 12-month low of $0.55 and a 12-month high of $1.81.

Atossa Therapeutics (NASDAQ:ATOS) last announced its quarterly earnings data on Tuesday, March 25th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01.

Hedge Funds Weigh In On Atossa Therapeutics

A number of large investors have recently modified their holdings of ATOS. Renaissance Technologies LLC boosted its holdings in Atossa Therapeutics by 18.9% in the 4th quarter. Renaissance Technologies LLC now owns 1,557,632 shares of the company’s stock valued at $1,471,000 after purchasing an additional 247,562 shares during the period. JPMorgan Chase & Co. raised its stake in Atossa Therapeutics by 141.4% in the fourth quarter. JPMorgan Chase & Co. now owns 361,296 shares of the company’s stock valued at $341,000 after purchasing an additional 211,654 shares in the last quarter. Virtu Financial LLC lifted its position in Atossa Therapeutics by 311.1% during the fourth quarter. Virtu Financial LLC now owns 208,196 shares of the company’s stock valued at $197,000 after purchasing an additional 157,549 shares during the last quarter. Barclays PLC grew its stake in Atossa Therapeutics by 280.9% in the 3rd quarter. Barclays PLC now owns 167,718 shares of the company’s stock worth $255,000 after buying an additional 123,683 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Atossa Therapeutics by 7.5% in the 4th quarter. Northern Trust Corp now owns 1,025,724 shares of the company’s stock worth $968,000 after buying an additional 71,525 shares during the last quarter. 12.74% of the stock is currently owned by institutional investors.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.